## Supporting Information

## Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration

Yuzhi Liang<sup>1,5#</sup>, Bing Wang<sup>1,5#</sup>, Qingjing Chen<sup>1,4#</sup>, Xingyue Fu<sup>1</sup>, Chenwei Jiang<sup>1</sup>, Zhiwen Lin<sup>1</sup>, Qiuyu Zhuang<sup>1, 3</sup>, Yongyi Zeng<sup>1,4</sup>, Xiaolong Liu<sup>1,2,3\*</sup>, Da Zhang<sup>1, 3\*</sup>

<sup>1</sup>The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China
<sup>2</sup>CAS Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, P. R. China
<sup>3</sup>Mengchao Med-X Center, Fuzhou University, Fuzhou 350116, P. R. China
<sup>4</sup>Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, People's Republic of China
<sup>5</sup>Fujian Agriculture and Forestry University, Fuzhou 350002, P. R. China
<sup>#</sup>Y. L, B. W and Q. C contributed equally to this works
\*Correspondence: Xiaolong Liu, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China
E-mail: xiaoloong.liu@gmail.com;

\*Correspondence: Da Zhang, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China E-mail: <u>zdluoman1987@163.com</u>;



Figure. S1. The gate and EGFP intensity of oHSV-treated Hepa1-6 cells were analyzed by FACS.



Figure S2. The TEM image of oHSV and glycosylated-PEG-oHSV.



Figure. S3. Standard curve for virus copy number determination.



**Figure S4.** Flow cytometry was performed on HepG2 cells treated with oHSV or glycosylated-PEG-oHSV. Statistical analysis was performed with t-test, \*p < 0.05, (n = 3). Data are presented as mean  $\pm$  SD.



**Figure. S5.** The gate and EGFP intensity of NIH/3T3 cells treated with oHSV were analyzed by FACS.



**Figure. S6.** Flow cytometry analysis and quantification of EGFP expression in NIH/3T3 cells after treatment with oHSV or glycosylated-PEG-oHSV for 12 h. Statistical analysis was performed using a t-test analysis, and significance levels were denoted by p<0.05, p<0.01, p<0.001, and p<0.0001. Data are presented as mean  $\pm$  standard deviation (SD).



**Figure. S7.** The cytolytic activity of Hepa1-6 cells treated with oHSV for 24 h was analyzed by FACS using Annexin V-FITC and PI staining.



**Figure. S8.** Biochemical analysis, including albumin, ALB; alkaline phosphatase, ALP; alanine aminotransferase, ALT; aspartate aminotransferase, AST; the blood urea nitrogen to serum creatinine ratio (BUN/SCR); and total cholesterol (TCHO) was performed in mice at the day 24 after intravenous injection of PBS, oHSV, or glycosylated-PEG-oHSV (n=3). Statistical analysis was conducted using ANOVA analysis, with significance levels denoted as \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, and \*\*\*\*p<0.0001. The data are presented as mean  $\pm$  standard deviation (SD).



**Figure. S9.** Identifying the maturation of lymphatic dendritic cells (DCs) from lymph nodes of mice after receiving different treatments by FACS analysis with staining using anti-CD11c-APC, anti-CD80-PE, and anti-CD86-PE-Cy7 antibodies.



**Figure. S10.** Identifying the percentage of CD8<sup>+</sup>T cells in spleen after receiving different treatments by FACS analysis with staining using anti-CD3-APC, anti-CD8-PE antibodies.



Figure S11. The percentage of CD3<sup>+</sup>CD4<sup>+</sup>T cells in tumors after treatment with PBS, oHSV or glycosylated- PEG-oHSV, respectively (n = 5).



**Figure. S12.** Identifying the percentage of CD8<sup>+</sup>T cells in tumors after receiving different treatments by FACS analysis with staining using anti-CD3-APC, anti-CD8-PE antibodies.





**Figure. S13.** Identifying IFN- $\gamma^+$ CD8<sup>+</sup>CD3<sup>+</sup>T cells in tumors after receiving different treatments by FACS analysis with staining using anti-CD3-APC, anti-CD8-PE, IFN- $\gamma$ -PE-Cy7 antibodies.

## Tumor



**Figure. S14.** Identifying NK cells in tumors after receiving different treatments by FACS analysis with staining using anti-CD3-FITC and anti-NK1.1-APC antibodies.



**Figure. S15.** Detection of Foxp3<sup>+</sup>CD25<sup>+</sup>CD4<sup>+</sup>T cells in tumors following different treatments by FACS analysis with staining using anti-CD3-APC, anti-CD4-FITC, anti-CD25-PerCP-Cy5.5, and anti-Foxp3-PE-Cy7 antibodies.



**Figure. S16.** Hematoxylin and eosin (H&E) imaging was performed on major organs including the heart, liver, spleen, lung, and kidney, obtained from mice at the day 24 after intravenous injection of PBS, oHSV, or glycosylated-PEG-oHSV. Scale bar, 100 µm.